Refractory Lung Cancer
Conditions
Interventions
Experimental Group:Neoantigen loaded-DC vaccine will be injected subcutaneously 6 times, once a week.
Sponsors
Shenzhen People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years at the time of informed consent; 2. Signed informed consent to be provided; 3. Pathologically confirmed lung cancer; 4. Failed in previous standard chemotherapy and targeted therapy; 5. Life expectancy not less than 90 days; 6. Karnofsky performance status 0-1; 7. Adequate organ functions.
Exclusion criteria
Exclusion criteria: 1. Actively infectious condition including hepatitis; 2. Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant; 3. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease); 4. Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities); 5. Active systemic infections, coagulation disorders or any other active major medical illnesses; 6. Patients who are receiving any other investigational agents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety of neoantigen-primed DC cells Vaccine;Immunogenicity of a neoantigen-primed DC cell Vaccine; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease Response;Objective Response Rate; | — |
Countries
China
Contacts
Public ContactLili Ren
Shenzhen People's Hospital
Outcome results
None listed